Lantheus Holdings, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 96/100
What the filing says
Curium US Holdings LLC agreed to acquire Lantheus Holdings for $102.50/share cash at close plus contingent value rights (CVRs) up to $12.00/share tied to sales milestones through 2030 for global prostate cancer diagnostics ($950M–$1,750M), neurology diagnostics ($300M–$350M), and DEFINITY ($400M+), totaling ~$8.0B. The transaction represents 38% premium to 60-day VWAP as of May 21, 2026. Lantheus Board unanimously approved after comprehensive strategic review including outreach to third parties. Expected close H1 2027 subject to shareholder and regulatory approvals.
Why this rating
Complete company sale at 38% premium materially exits public markets; ~186% of $4.3B market cap represents transformational M&A. Highest-tier business event.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.